Research

Insights for Safe Consumption (Part 2)

November 15, 2022
|
The EO Team

We recently discussed a study in which we found smoking cannabis was popular within a sample of medical cannabis dispensary users. We found smoking cannabis was associated with greater cannabis use and preference for THC-dominant chemovars and was associated with concurrent alcohol use disorder. These findings provided several key insights into risks and harm reduction strategies for people smoking cannabis with a medical intent.

Our takeaways included: 

1. Cannabis smokers are at a greater risk for adverse outcomes: 

     - Smoking poses a respiratory risk 

     - More frequent use of THC may lead to a higher chance of side effects such as impairment or sedation 

2. A key harm reduction strategy may be educating on how to better control symptoms with the least amount of harm:

     - This includes better utilizing CBD

     - Vaporization as an alternative inhalation method

3. The benefits of dried product vaporization should be more widely available: 

     - Vaporization of dried cannabis flower has a lower respiratory risk compared to smoking 

     - Dried flower is cheaper than cannabis oils or edibles, which may be useful for individuals with alcohol use disorder and may need to afford both substances

     - It is important to use a dried product vaporizer compared to an electronic cigarette, which uses concentrated product, as concentrates may also contain harmful toxins 

     - Regulated product should always be used when possible to ensure the product being consumed does not contain contaminants or toxins

What this might mean for you:

1. If you want to inhale your cannabis, use dried-product vaporization from a regulated source (a licensed dispensary, medical treatment center, or caregiver).

2. Remember that one of the goals of medical cannabis use is to use the lowest doses possible that allow for adequate symptom control, especially for THC. This can be done by first trying CBD-dominant or 1:1 CBD:THC strains. If greater symptom relief is needed, slowly increase the amount of THC you use. 

Dr. Caroline MacCallum is a specialist in internal medicine with expertise in complex pain and cannabinoid medicine. In addition to serving as an advisor to EO Care, she is a clinical instructor in the Department of Medicine; Adjunct Professor in the Faculty of Pharmaceutical Sciences program; and associate member in the Dept. of Palliative Care at the University of British Columbia. An avid researcher, Dr. MacCallum is primary author of Practical Considerations for Medical Cannabis Administration and Dosing, and assistant editor for Cannabinoids and Pain.

Here's where you can find Dr. Caroline MacCallum online:

- Instagram: @dr.carolinemaccallum

- Twitter: @camaccallum

- Facebook: Dr. Caroline MacCallum

- Linkedin: Dr. Caroline MacCallum, MD

- Website: https://drcarolinemaccallum.com/

<-  Back to blog
More
Research
Research

Cannabis and Cancer

Navigating a cancer diagnosis is one of the most difficult life challenges a person can face. Two-time cancer survivor and EO spokesperson Ethan Zohn says, “cancer is a disease that touches every part of you as a human being: mental, physical, social, spiritual. You’re always just looking for ways to make yourself feel better.”

Read More
Read More
Research

Gabapentin and Thc

Gabapentin and cannabis are two substances frequently used to help manage pain and a range of other health conditions. While gabapentin is primarily used to help treat nerve pain, seizures and shingles-related discomfort, cannabis is well known for its analgesic, anti-inflammatory and relaxation-inducing effects.

Read More
Read More
Research

THC Inhaler vs Vape

A growing body of research illustrates the untapped potential of cannabis for a range of medical uses, like helping to manage pain, stress, sleep and appetite. However, studies also indicate that alternative methods of intake are necessary to create consistent, repeatable effects and to reduce the risks associated with smoking cannabis. According to a scientific review by the Institute of Medicine, “the future of cannabinoid drugs lies not in smoked marijuana but in chemically defined drugs that act on the cannabinoid systems that are a natural component of human physiology.”

Read More
Read More